Evidence map›Paper›PMID 36695896›Full record

ArticleActa neuropathologica2023

Persistent virus-specific and clonally expanded antibody-secreting cells respond to induced self-antigen in the CNS.

Andreas Agrafiotis, Raphael Dizerens, Ilena Vincenti, Ingrid Wagner, Raphael Kuhn, Danielle Shlesinger, Marcos Manero-Carranza, Tudor-Stefan Cotet, Kai-Lin Hong, Nicolas Page and 21 more

Open access · hybridAbstract read
In one paragraph

Article in Acta neuropathologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 8 institutions in 2 countries.

Andreas AgrafiotisDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Raphael DizerensDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Ilena VincentiDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Ingrid WagnerDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Raphael KuhnDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Danielle ShlesingerDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Marcos Manero-CarranzaDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Tudor-Stefan CotetDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Kai-Lin HongDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Nicolas PageDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Nicolas FontaDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Ghazal ShammasDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Alexandre MariotteDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Margot PiccinnoDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Mario KreutzfeldtDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Benedikt GruntzDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Roy EhlingDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Alessandro GenoveseInstitute of Microbiology, ETH Zurich, Zurich, Switzerland.
Alessandro PedrioliInstitute of Microbiology, ETH Zurich, Zurich, Switzerland.
Andreas DounasInstitute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland.
Sören FranzenburgInstitute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Kiel, Germany.
Hayrettin TumaniDepartment of Neurology, University Hospital Ulm, Ulm, Germany.
Tania KümpfelInstitute of Clinical Neuroimmunology, Faculty of Medicine, University Hospital and Biomedical Center (BMC), LMU Munich, Munich, Germany.
Vladyslav KavakaInstitute of Clinical Neuroimmunology, Faculty of Medicine, University Hospital and Biomedical Center (BMC), LMU Munich, Munich, Germany.
Lisa Ann GerdesInstitute of Clinical Neuroimmunology, Faculty of Medicine, University Hospital and Biomedical Center (BMC), LMU Munich, Munich, Germany.
Klaus DornmairInstitute of Clinical Neuroimmunology, Faculty of Medicine, University Hospital and Biomedical Center (BMC), LMU Munich, Munich, Germany.
Eduardo BeltránInstitute of Clinical Neuroimmunology, Faculty of Medicine, University Hospital and Biomedical Center (BMC), LMU Munich, Munich, Germany.
Annette OxeniusInstitute of Microbiology, ETH Zurich, Zurich, Switzerland.
Sai T ReddyDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
Doron MerklerDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland. Doron.Merkler@unige.ch.
Alexander YermanosDepartment of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland. ayermanos@gmail.com.
ETH Zurich · CHUniversity of Geneva · CHLudwig-Maximilians-Universität München · DEMunich Cluster for Systems Neurology · DEInstitute for Biomedical Engineering · CHKiel University · DEMax Planck Institute of Neurobiology · DEUniversity Hospital Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B cells contribute to the pathogenesis of both cellular- and humoral-mediated central nervous system (CNS) inflammatory diseases through a variety of mechanisms. In such conditions, B cells may enter the CNS parenchyma and contribute to local tissue destruction. It remains unexplored, however, how infection and autoimmunity drive transcriptional phenotypes, repertoire features, and antibody functionality. Here, we profiled B cells from the CNS of murine models of intracranial (i.c.) viral infections and autoimmunity. We identified a population of clonally expanded, antibody-secreting cells (ASCs) that had undergone class-switch recombination and extensive somatic hypermutation following i.c. infection with attenuated lymphocytic choriomeningitis virus (rLCMV). Recombinant expression and characterisation of these antibodies revealed specificity to viral antigens (LCMV glycoprotein GP), correlating with ASC persistence in the brain weeks after resolved infection. Furthermore, these virus-specific ASCs upregulated proliferation and expansion programs in response to the conditional and transient induction of the LCMV GP as a neo-self antigen by astrocytes. This class-switched, clonally expanded, and mutated population persisted and was even more pronounced when peripheral B cells were depleted prior to autoantigen induction in the CNS. In contrast, the most expanded B cell clones in mice with persistent expression of LCMV GP in the CNS did not exhibit neo-self antigen specificity, potentially a consequence of local tolerance induction. Finally, a comparable population of clonally expanded, class-switched, and proliferating ASCs was detected in the cerebrospinal fluid of relapsing multiple sclerosis (RMS) patients. Taken together, our findings support the existence of B cells that populate the CNS and are capable of responding to locally encountered autoantigens.

Indexed as

Antibody-Producing CellsAutoantigensAnimalsB-LymphocytesBrainLymphocytic choriomeningitis virusMiceAutoantigensAntibody-secreting cellsAutoimmunityCNS toleranceMultiple sclerosisViral infection

Identifiers

PMID36695896
PMCPMC9925600
OpenAlexW4317888784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.